Improving platelet transfusion safety: biomedical and technical considerations.

Détails

ID Serval
serval:BIB_336CFB39CE09
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Improving platelet transfusion safety: biomedical and technical considerations.
Périodique
Blood Transfusion
Auteur(s)
Garraud O., Cognasse F., Tissot J.D., Chavarin P., Laperche S., Morel P., Lefrère J.J., Pozzetto B., Lozano M., Blumberg N., Osselaer J.C.
ISSN
1723-2007 (Print)
ISSN-L
1723-2007
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
14
Numéro
2
Pages
109-122
Langue
anglais
Résumé
Platelet concentrates account for near 10% of all labile blood components but are responsible for more than 25% of the reported adverse events. Besides factors related to patients themselves, who may be particularly at risk of side effects because of their underlying illness, there are aspects of platelet collection and storage that predispose to adverse events. Platelets for transfusion are strongly activated by collection through disposal equipment, which can stress the cells, and by preservation at 22 °C with rotation or rocking, which likewise leads to platelet activation, perhaps more so than storage at 4 °C. Lastly, platelets constitutively possess a very large number of bioactive components that may elicit pro-inflammatory reactions when infused into a patient. This review aims to describe approaches that may be crucial to minimising side effects while optimising safety and quality. We suggest that platelet transfusion is complex, in part because of the complexity of the "material" itself: platelets are highly versatile cells and the transfusion process adds a myriad of variables that present many challenges for preserving basal platelet function and preventing dysfunctional activation of the platelets. The review also presents information showing - after years of exhaustive haemovigilance - that whole blood buffy coat pooled platelet components are extremely safe compared to the gold standard (i.e. apheresis platelet components), both in terms of acquired infections and of immunological/inflammatory hazards.
Pubmed
Création de la notice
10/03/2016 10:33
Dernière modification de la notice
20/08/2019 14:19
Données d'usage